{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:18:51Z","timestamp":1763018331439,"version":"3.40.3"},"publisher-location":"Cham","reference-count":125,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783030660130"},{"type":"electronic","value":"9783030660147"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-3-030-66014-7_12","type":"book-chapter","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T15:18:16Z","timestamp":1618327096000},"page":"295-314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Current Management of Age-Related Macular Degeneration"],"prefix":"10.1007","author":[{"given":"Cindy","family":"Ung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ines","family":"Lains","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan W.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana K.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,14]]},"reference":[{"key":"12_CR1","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/archopht.119.10.1417","volume":"119","author":"Age-Related Eye Disease Study Research Group","year":"2001","unstructured":"Age-Related Eye Disease Study Research Group (2001) A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 119:1417\u20131436","journal-title":"Arch Ophthalmol"},{"key":"12_CR2","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1001\/archopht.123.11.1570","volume":"123","author":"FL Ferris","year":"2005","unstructured":"Ferris FL, Davis MD, Clemons TE et al (2005) A simplified severity scale for age-related macular degeneration: AREDS report no. 18. Arch Ophthalmol 123:1570\u20131574. https:\/\/doi.org\/10.1001\/archopht.123.11.1570","journal-title":"Arch Ophthalmol"},{"key":"12_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/IIO.0b013e31802bd785","volume":"47","author":"C Cukras","year":"2007","unstructured":"Cukras C, Fine SL (2007) Classification and grading system for age-related macular degeneration. Int Ophthalmol Clin 47:51\u201363","journal-title":"Int Ophthalmol Clin"},{"key":"12_CR4","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","volume":"120","author":"FL Ferris","year":"2013","unstructured":"Ferris FL, Wilkinson CP, Bird A et al (2013) Clinical classification of age-related macular degeneration. Ophthalmology 120:844\u2013851","journal-title":"Ophthalmology"},{"key":"12_CR5","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1001\/jamaophthalmol.2017.0830","volume":"135","author":"DC Neely","year":"2017","unstructured":"Neely DC, Bray KJ, Huisingh CE et al (2017) Prevalence of undiagnosed age-related macular degeneration in primary eye care. JAMA Ophthalmol 135:570. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.0830","journal-title":"JAMA Ophthalmol"},{"key":"12_CR6","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1001\/jamaophthalmol.2017.3782","volume":"135","author":"PM Burlina","year":"2017","unstructured":"Burlina PM, Joshi N, Pekala M et al (2017) Automated grading of age-related macular degeneration from color fundus images using deep convolutional neural networks. JAMA Ophthalmol 135:1170. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.3782","journal-title":"JAMA Ophthalmol"},{"key":"12_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1089\/tmj.2017.0100","volume":"24","author":"A Kawaguchi","year":"2018","unstructured":"Kawaguchi A, Sharafeldin N, Sundaram A et al (2018) Tele-ophthalmology for age-related macular degeneration and diabetic retinopathy screening: A systematic review and meta-analysis. Telemed e-Health 24:301\u2013308. https:\/\/doi.org\/10.1089\/tmj.2017.0100","journal-title":"Telemed e-Health"},{"key":"12_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0002-9394(14)75576-X","volume":"109","author":"D Pauleikhoff","year":"1990","unstructured":"Pauleikhoff D, Barondes MJ, Minassian D et al (1990) Drusen as risk factors in age-related macular disease. Am J Ophthalmol 109:38\u201343","journal-title":"Am J Ophthalmol"},{"key":"12_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ophtha.2006.10.040","volume":"114","author":"R Klein","year":"2007","unstructured":"Klein R, Klein BEK, Knudtson MD et al (2007) Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 114:253\u2013262. https:\/\/doi.org\/10.1016\/j.ophtha.2006.10.040","journal-title":"Ophthalmology"},{"key":"12_CR10","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.ophtha.2007.08.030","volume":"115","author":"ML Klein","year":"2008","unstructured":"Klein ML, Ferris FL, Armstrong J et al (2008) Retinal precursors and the development of geographic atrophy in age-related macular degeneration. Ophthalmology 115:1026\u20131031. https:\/\/doi.org\/10.1016\/j.ophtha.2007.08.030","journal-title":"Ophthalmology"},{"key":"12_CR11","doi-asserted-by":"publisher","first-page":"7093","DOI":"10.1167\/iovs.14-14918","volume":"55","author":"L de Sisternes","year":"2014","unstructured":"de Sisternes L, Simon N, Tibshirani R et al (2014) Quantitative SD-OCT imaging biomarkers as indicators of age-related macular degeneration progression. Investig Opthalmology Vis Sci 55:7093. https:\/\/doi.org\/10.1167\/iovs.14-14918","journal-title":"Investig Opthalmology Vis Sci"},{"key":"12_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.07.007","volume":"50","author":"U Schmidt-Erfurth","year":"2016","unstructured":"Schmidt-Erfurth U, Waldstein SM (2016) A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res 50:1\u201324. https:\/\/doi.org\/10.1016\/j.preteyeres.2015.07.007","journal-title":"Prog Retin Eye Res"},{"key":"12_CR13","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ophtha.2012.07.004","volume":"120","author":"JN Leuschen","year":"2013","unstructured":"Leuschen JN, Schuman SG, Winter KP et al (2013) Spectral-domain optical coherence tomography characteristics of intermediate age-related macular degeneration. Ophthalmology 120:140\u2013150. https:\/\/doi.org\/10.1016\/j.ophtha.2012.07.004","journal-title":"Ophthalmology"},{"key":"12_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/eye.2016.227","volume":"31","author":"U Schmidt-Erfurth","year":"2017","unstructured":"Schmidt-Erfurth U, Klimscha S, Waldstein SM, Bogunovi\u0107 H (2017) A view of the current and future role of optical coherence tomography in the management of age-related macular degeneration. Eye 31:26\u201344. https:\/\/doi.org\/10.1038\/eye.2016.227","journal-title":"Eye"},{"key":"12_CR15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ophtha.2009.07.014","volume":"117","author":"SA Zweifel","year":"2010","unstructured":"Zweifel SA, Spaide RF, Curcio CA et al (2010) Reticular pseudodrusen are subretinal drusenoid deposits. Ophthalmology 117:303\u2013312.e1. https:\/\/doi.org\/10.1016\/j.ophtha.2009.07.014","journal-title":"Ophthalmology"},{"key":"12_CR16","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1097\/IAE.0b013e3182247535","volume":"31","author":"RF Spaide","year":"2011","unstructured":"Spaide RF, Curcio CA (2011) Anatomical correlates to the bands seen in the outer retina by optical coherence tomography: literature review and model. Retina 31:1609\u20131619. https:\/\/doi.org\/10.1097\/IAE.0b013e3182247535","journal-title":"Retina"},{"key":"12_CR17","doi-asserted-by":"publisher","first-page":"7362","DOI":"10.1167\/iovs.12-11073","volume":"54","author":"M Marsiglia","year":"2013","unstructured":"Marsiglia M, Boddu S, Bearelly S et al (2013) Association between geographic atrophy progression and reticular pseudodrusen in eyes with dry age-related macular degeneration. Investig Ophthalmol Vis Sci 54:7362\u20137369. https:\/\/doi.org\/10.1167\/iovs.12-11073","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"12_CR18","doi-asserted-by":"publisher","first-page":"5743","DOI":"10.1167\/iovs.10-6942","volume":"52","author":"MA Sohrab","year":"2011","unstructured":"Sohrab MA, Smith RT, Salehi-Had H et al (2011) Image registration and multimodal imaging of reticular pseudodrusen. Invest Ophthalmol Vis Sci 52:5743\u20135748. https:\/\/doi.org\/10.1167\/iovs.10-6942","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"12_CR19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.ajo.2009.06.028","volume":"148","author":"RT Smith","year":"2009","unstructured":"Smith RT, Sohrab MA, Busuioc M, Barile G (2009) Reticular macular disease. Am J Ophthalmol 148:733\u2013743.e2. https:\/\/doi.org\/10.1016\/j.ajo.2009.06.028","journal-title":"Am J Ophthalmol"},{"key":"12_CR20","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/IAE.0b013e318276e0ae","volume":"33","author":"N Ueda-Arakawa","year":"2013","unstructured":"Ueda-Arakawa N, Ooto S, Tsujikawa A et al (2013) Sensitivity and specificity of detecting reticular pseudodrusen in multimodal imaging in Japanese patients. Retina 33:490\u2013497. https:\/\/doi.org\/10.1097\/IAE.0b013e318276e0ae","journal-title":"Retina"},{"key":"12_CR21","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.ophtha.2017.03.043","volume":"124","author":"R Dolz-Marco","year":"2017","unstructured":"Dolz-Marco R, Litts KM, Tan ACS et al (2017) The evolution of outer retinal tubulation, a neurodegeneration and gliosis prominent in macular diseases. Ophthalmology 124:1353\u20131367. https:\/\/doi.org\/10.1016\/j.ophtha.2017.03.043","journal-title":"Ophthalmology"},{"key":"12_CR22","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ophtha.2014.08.035","volume":"122","author":"A Hariri","year":"2015","unstructured":"Hariri A, Nittala MG, Sadda SR (2015) Outer retinal tubulation as a predictor of the enlargement amount of geographic atrophy in age-related macular degeneration. Ophthalmology 122:407\u2013413. https:\/\/doi.org\/10.1016\/j.ophtha.2014.08.035","journal-title":"Ophthalmology"},{"key":"12_CR23","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/j.ophtha.2017.06.032","volume":"124","author":"K Sleiman","year":"2017","unstructured":"Sleiman K, Veerappan M, Winter KP et al (2017) Optical coherence tomography predictors of risk for progression to non-neovascular atrophic age-related macular degeneration. Ophthalmology 124:1764\u20131777. https:\/\/doi.org\/10.1016\/j.ophtha.2017.06.032","journal-title":"Ophthalmology"},{"key":"12_CR24","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1167\/iovs.17-21696","volume":"58","author":"D Ferrara","year":"2017","unstructured":"Ferrara D, Silver RE, Louzada RN et al (2017) Optical coherence tomography features preceding the onset of advanced age-related macular degeneration. Invest Ophthalmol Vis Sci 58:3519\u20133529. https:\/\/doi.org\/10.1167\/iovs.17-21696","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"12_CR25","doi-asserted-by":"publisher","unstructured":"Yu JJ, Agr\u00f3n E, Clemons TE et al (2018) Natural history of drusenoid pigment epithelial detachment associated with age-related macular degeneration. Ophthalmology. https:\/\/doi.org\/10.1016\/j.ophtha.2018.08.017","DOI":"10.1016\/j.ophtha.2018.08.017"},{"key":"12_CR26","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ophtha.2016.12.002","volume":"124","author":"FG Holz","year":"2017","unstructured":"Holz FG, Sadda SR, Staurenghi G et al (2017) Imaging protocols in clinical studies in advanced age-related macular degeneration. Ophthalmology 124:464\u2013478. https:\/\/doi.org\/10.1016\/j.ophtha.2016.12.002","journal-title":"Ophthalmology"},{"key":"12_CR27","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1097\/IAE.0000000000001258","volume":"36","author":"S Schmitz-Valckenberg","year":"2016","unstructured":"Schmitz-Valckenberg S, Sadda S, Staurenghi G et al (2016) Geographic atrophy: semantic considerations and literature review. Retina 36:2250\u20132264. https:\/\/doi.org\/10.1097\/IAE.0000000000001258","journal-title":"Retina"},{"key":"12_CR28","doi-asserted-by":"publisher","unstructured":"Mantel I, Zola M, De Massougnes S et al (2018) Factors influencing macular atrophy growth rates in neovascular age-related macular degeneration treated with ranibizumab or aflibercept according to an observe-and-plan regimen. Br J Ophthalmol. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-312430","DOI":"10.1136\/bjophthalmol-2018-312430"},{"key":"12_CR29","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.ophtha.2017.11.036","volume":"125","author":"U Chakravarthy","year":"2018","unstructured":"Chakravarthy U, Bailey CC, Johnston RL et al (2018) Characterizing disease burden and progression of geographic atrophy secondary to age-related macular degeneration. Ophthalmology 125:842\u2013849. https:\/\/doi.org\/10.1016\/j.ophtha.2017.11.036","journal-title":"Ophthalmology"},{"key":"12_CR30","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1001\/archopht.1991.01080090066027","volume":"109","author":"Macular photocoagulation Study Group","year":"1991","unstructured":"Macular photocoagulation Study Group (1991) Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Macular Photocoagulation Study Group. Arch Ophthalmol (Chicago, IL 1960) 109:1242\u20131257","journal-title":"Arch Ophthalmol (Chicago, IL 1960)"},{"key":"12_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/00055735-199506000-00005","volume":"6","author":"JS Slakter","year":"1995","unstructured":"Slakter JS, Yannuzzi LA, Guyer DR et al (1995) Indocyanine-green angiography. Curr Opin Ophthalmol 6:25\u201332","journal-title":"Curr Opin Ophthalmol"},{"key":"12_CR32","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","volume":"125","author":"CMG Cheung","year":"2018","unstructured":"Cheung CMG, Lai TYY, Ruamviboonsuk P et al (2018) Polypoidal choroidal vasculopathy. Ophthalmology 125:708\u2013724. https:\/\/doi.org\/10.1016\/j.ophtha.2017.11.019","journal-title":"Ophthalmology"},{"key":"12_CR33","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/2474126417725946","volume":"1","author":"D Brown","year":"2017","unstructured":"Brown D, Heier JS, Boyer DS et al (2017) Current best clinical practices\u2014management of neovascular AMD. J Vitreoretin Dis 1:294\u2013297. https:\/\/doi.org\/10.1177\/2474126417725946","journal-title":"J Vitreoretin Dis"},{"key":"12_CR34","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1177\/1120672118766807","volume":"28","author":"M Lupidi","year":"2018","unstructured":"Lupidi M, Cerquaglia A, Chhablani J et al (2018) Optical coherence tomography angiography in age-related macular degeneration: the game changer. Eur J Ophthalmol 28:349\u2013357. https:\/\/doi.org\/10.1177\/1120672118766807","journal-title":"Eur J Ophthalmol"},{"key":"12_CR35","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/IAE.0000000000001628","volume":"38","author":"M Al-Sheikh","year":"2018","unstructured":"Al-Sheikh M, Iafe NA, Phasukkijwatana N et al (2018) Biomarkers of neovascular activity in age-related macular degeneration using optical coherence tomography angiography. Retina 38:220\u2013230. https:\/\/doi.org\/10.1097\/IAE.0000000000001628","journal-title":"Retina"},{"key":"12_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2017.11.003","volume":"64","author":"RF Spaide","year":"2018","unstructured":"Spaide RF, Fujimoto JG, Waheed NK et al (2018) Optical coherence tomography angiography. Prog Retin Eye Res 64:1\u201355. https:\/\/doi.org\/10.1016\/j.preteyeres.2017.11.003","journal-title":"Prog Retin Eye Res"},{"key":"12_CR37","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ophtha.2017.08.030","volume":"125","author":"JR de Oliveira Dias","year":"2018","unstructured":"de Oliveira Dias JR, Zhang Q, Garcia JMB et al (2018) Natural history of subclinical neovascularization in nonexudative age-related macular degeneration using swept-source OCT angiography. Ophthalmology 125:255\u2013266. https:\/\/doi.org\/10.1016\/j.ophtha.2017.08.030","journal-title":"Ophthalmology"},{"key":"12_CR38","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ajo.2010.01.007","volume":"149","author":"IA Barbazetto","year":"2010","unstructured":"Barbazetto IA, Saroj N, Shapiro H et al (2010) Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. Am J Ophthalmol 149:939\u2013946.e1. https:\/\/doi.org\/10.1016\/j.ajo.2010.01.007","journal-title":"Am J Ophthalmol"},{"key":"12_CR39","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1016\/j.ophtha.2013.03.017","volume":"120","author":"MG Maguire","year":"2013","unstructured":"Maguire MG, Daniel E, Shah AR et al (2013) Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology 120:2035\u20132041. https:\/\/doi.org\/10.1016\/j.ophtha.2013.03.017","journal-title":"Ophthalmology"},{"key":"12_CR40","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1167\/iovs.15-18962","volume":"57","author":"C Owsley","year":"2016","unstructured":"Owsley C, Clark ME, Huisingh CE et al (2016) Visual function in older eyes in normal macular health: association with incident early age-related macular degeneration 3 years later. Investig Opthalmology Vis Sci 57:1782. https:\/\/doi.org\/10.1167\/iovs.15-18962","journal-title":"Investig Opthalmology Vis Sci"},{"key":"12_CR41","first-page":"1","volume":"41","author":"C Owsley","year":"2015","unstructured":"Owsley C, Huisingh C, Clark ME et al (2015) Comparison of visual function in older eyes in the earliest stages of age-related macular degeneration to those in normal macular health. Curr Eye Res 41:1\u20137","journal-title":"Curr Eye Res"},{"key":"12_CR42","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ajo.2018.02.012","volume":"189","author":"KJ Cocce","year":"2018","unstructured":"Cocce KJ, Stinnett SS, Luhmann UFO et al (2018) Visual function metrics in early and intermediate dry age-related macular degeneration for use as clinical trial endpoints. Am J Ophthalmol 189:127\u2013138. https:\/\/doi.org\/10.1016\/j.ajo.2018.02.012","journal-title":"Am J Ophthalmol"},{"key":"12_CR43","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1167\/iovs.05-1419","volume":"47","author":"SA Haymes","year":"2006","unstructured":"Haymes SA, Roberts KF, Cruess AF et al (2006) The letter contrast sensitivity test: clinical evaluation of a new design. Invest Ophthalmol Vis Sci 47:2739\u20132745. https:\/\/doi.org\/10.1167\/iovs.05-1419","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"12_CR44","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.preteyeres.2005.11.002","volume":"25","author":"RE Hogg","year":"2006","unstructured":"Hogg RE, Chakravarthy U (2006) Visual function and dysfunction in early and late age-related maculopathy. Prog Retin Eye Res 25:249\u2013276. https:\/\/doi.org\/10.1016\/j.preteyeres.2005.11.002","journal-title":"Prog Retin Eye Res"},{"key":"12_CR45","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000320340","volume":"225","author":"S Vujosevic","year":"2011","unstructured":"Vujosevic S, Smolek MK, Lebow KA et al (2011) Detection of macular function changes in early (AREDS 2) and intermediate (AREDS 3) age-related macular degeneration. Ophthalmol J Int d\u2019ophtalmologie Int J Ophthalmol Zeitschrift f\u00fcr Augenheilkd 225:155\u2013160. https:\/\/doi.org\/10.1159\/000320340","journal-title":"Ophthalmol J Int d\u2019ophtalmologie Int J Ophthalmol Zeitschrift f\u00fcr Augenheilkd"},{"key":"12_CR46","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1167\/iovs.13-13745","volume":"55","author":"GR Jackson","year":"2014","unstructured":"Jackson GR, Scott IU, Kim IK et al (2014) Diagnostic sensitivity and specificity of dark adaptometry for detection of age-related macular degeneration. Invest Ophthalmol Vis Sci 55:1427\u20131431. https:\/\/doi.org\/10.1167\/iovs.13-13745","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"12_CR47","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.ophtha.2006.12.023","volume":"114","author":"C Owsley","year":"2007","unstructured":"Owsley C, McGwin G, Jackson GR et al (2007) Cone- and rod-mediated dark adaptation impairment in age-related maculopathy. Ophthalmology 114:1728\u20131735","journal-title":"Ophthalmology"},{"key":"12_CR48","doi-asserted-by":"publisher","unstructured":"La\u00edns I, Miller JB, Park DH et al (2016) Structural changes associated with delayed dark adaptation in age-related macular degeneration. Ophthalmology. https:\/\/doi.org\/10.1016\/j.ophtha.2017.03.061","DOI":"10.1016\/j.ophtha.2017.03.061"},{"key":"12_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/895147","volume":"2013","author":"S Velilla","year":"2013","unstructured":"Velilla S, Garc\u00eda-Medina JJ, Garc\u00eda-Layana A et al (2013) Smoking and age-related macular degeneration: review and update. J Ophthalmol 2013:1\u201311. https:\/\/doi.org\/10.1155\/2013\/895147","journal-title":"J Ophthalmol"},{"key":"12_CR50","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.2147\/CIA.S142685","volume":"12","author":"A Garcia-Layana","year":"2017","unstructured":"Garcia-Layana A, Cabrera-L\u00f3pez F, Garc\u00eda-Arum\u00ed J et al (2017) Early and intermediate age-related macular degeneration: update and clinical review. Clin Interv Aging 12:1579\u20131587. https:\/\/doi.org\/10.2147\/CIA.S142685","journal-title":"Clin Interv Aging"},{"key":"12_CR51","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.annepidem.2008.04.002","volume":"18","author":"R Cong","year":"2008","unstructured":"Cong R, Zhou B, Sun Q et al (2008) Smoking and the risk of age-related macular degeneration: a meta-analysis. Ann Epidemiol 18:647\u2013656. https:\/\/doi.org\/10.1016\/j.annepidem.2008.04.002","journal-title":"Ann Epidemiol"},{"key":"12_CR52","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/bjo.2005.073643","volume":"90","author":"JC Khan","year":"2006","unstructured":"Khan JC, Thurlby DA, Shahid H et al (2006) Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol 90:75\u201380. https:\/\/doi.org\/10.1136\/bjo.2005.073643","journal-title":"Br J Ophthalmol"},{"key":"12_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-016-0063-5","volume":"3","author":"KL Pennington","year":"2016","unstructured":"Pennington KL, DeAngelis MM (2016) Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis 3:34. https:\/\/doi.org\/10.1186\/s40662-016-0063-5","journal-title":"Eye Vis"},{"key":"12_CR54","doi-asserted-by":"publisher","unstructured":"Chapman NA, Jacobs RJ, Braakhuis AJ (2018) Role of diet and food intake in age-related macular degeneration: a systematic review. Clin Exp Ophthalmol. https:\/\/doi.org\/10.1111\/ceo.13343","DOI":"10.1111\/ceo.13343"},{"key":"12_CR55","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ophtha.2004.10.047","volume":"112","author":"TE Clemons","year":"2005","unstructured":"Clemons TE, Milton RC, Klein R et al (2005) Risk factors for the incidence of advanced age-related macular degeneration in the age-related eye disease study (AREDS) AREDS report no. 19. Ophthalmology 112:533\u2013539.e1. https:\/\/doi.org\/10.1016\/j.ophtha.2004.10.047","journal-title":"Ophthalmology"},{"key":"12_CR56","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1001\/jama.2013.4997","volume":"309","author":"Age-Related Eye Disease Study 2 Research Group","year":"2013","unstructured":"Age-Related Eye Disease Study 2 Research Group (2013) Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 309:2005\u20132015","journal-title":"JAMA"},{"key":"12_CR57","doi-asserted-by":"publisher","first-page":"E696","DOI":"10.1073\/pnas.1718059115","volume":"115","author":"DG Vavvas","year":"2018","unstructured":"Vavvas DG, Small KW, Awh CC et al (2018) CFH and ARMS2 genetic risk determines progression to neovascular age-related macular degeneration after antioxidant and zinc supplementation. Proc Natl Acad Sci U S A 115:E696\u2013E704. https:\/\/doi.org\/10.1073\/pnas.1718059115","journal-title":"Proc Natl Acad Sci U S A"},{"key":"12_CR58","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2017.09.008","volume":"125","author":"MJ Assel","year":"2018","unstructured":"Assel MJ, Li F, Wang Y et al (2018) Genetic polymorphisms of CFH and ARMS2 do not predict response to antioxidants and zinc in patients with age-related macular degeneration. Ophthalmology 125:391\u2013397. https:\/\/doi.org\/10.1016\/j.ophtha.2017.09.008","journal-title":"Ophthalmology"},{"key":"12_CR59","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ophtha.2014.10.012","volume":"122","author":"EY Chew","year":"2015","unstructured":"Chew EY, Klein ML, Clemons TE et al (2015) Genetic testing in persons with age-related macular degeneration and the use of the AREDS supplements: to test or not to test? Ophthalmology 122:212\u2013215. https:\/\/doi.org\/10.1016\/j.ophtha.2014.10.012","journal-title":"Ophthalmology"},{"key":"12_CR60","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1016\/j.ophtha.2015.01.031","volume":"122","author":"J Pearlman","year":"2015","unstructured":"Pearlman J (2015) Re: Chew et al.: Genetic testing in persons with age-related macular degeneration and the use of the AREDS supplements: to test or not to test? (Ophthalmology 2015;122:212-5). Ophthalmology 122:e60\u2013e61. https:\/\/doi.org\/10.1016\/j.ophtha.2015.01.031","journal-title":"Ophthalmology"},{"key":"12_CR61","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1016\/j.ophtha.2015.03.028","volume":"122","author":"CC Awh","year":"2015","unstructured":"Awh CC, Zanke B (2015) Re: Chew et al.: Genetic testing in persons with age-related macular degeneration and the use of AREDS supplements: to test or not to test? (Ophthalmology 2015;122:212-5). Ophthalmology 122:e62\u2013e63. https:\/\/doi.org\/10.1016\/j.ophtha.2015.03.028","journal-title":"Ophthalmology"},{"key":"12_CR62","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/j.ophtha.2014.05.008","volume":"121","author":"EY Chew","year":"2014","unstructured":"Chew EY, Klein ML, Clemons TE et al (2014) No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology 121:2173\u20132180. https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.008","journal-title":"Ophthalmology"},{"key":"12_CR63","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.ophtha.2008.01.036","volume":"115","author":"ML Klein","year":"2008","unstructured":"Klein ML, Francis PJ, Rosner B et al (2008) CFH and LOC387715\/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. Ophthalmology 115:1019\u20131025. https:\/\/doi.org\/10.1016\/j.ophtha.2008.01.036","journal-title":"Ophthalmology"},{"key":"12_CR64","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/j.ophtha.2013.07.039","volume":"120","author":"CC Awh","year":"2013","unstructured":"Awh CC, Lane A-M, Hawken S et al (2013) CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration. Ophthalmology 120:2317\u20132323. https:\/\/doi.org\/10.1016\/j.ophtha.2013.07.039","journal-title":"Ophthalmology"},{"key":"12_CR65","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2017.09.008","volume":"125","author":"MJ Assel","year":"2018","unstructured":"Assel MJ, Li F, Wang Y et al (2018) Genetic polymorphisms of CFH and ARMS2 do not predict response to antioxidants and zinc in patients with age-related macular degeneration: independent statistical evaluations of data from the Age-Related Eye Disease Study. Ophthalmology 125:391\u2013397. https:\/\/doi.org\/10.1016\/j.ophtha.2017.09.008","journal-title":"Ophthalmology"},{"key":"12_CR66","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/eye.2014.104","volume":"28","author":"L Faes","year":"2014","unstructured":"Faes L, Bodmer NS, Bachmann LM et al (2014) Diagnostic accuracy of the Amsler grid and the preferential hyperacuity perimetry in the screening of patients with age-related macular degeneration: systematic review and meta-analysis. Eye (Lond) 28:788\u2013796. https:\/\/doi.org\/10.1038\/eye.2014.104","journal-title":"Eye (Lond)"},{"key":"12_CR67","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1097\/IAE.0b013e3182018df6","volume":"32","author":"R Rauch","year":"2012","unstructured":"Rauch R, Weingessel B, Maca SM, Vecsei-Marlovits PV (2012) Time to first treatment: the significance of early treatment of exudative age-related macular degeneration. Retina 32:1260\u20131264. https:\/\/doi.org\/10.1097\/IAE.0b013e3182018df6","journal-title":"Retina"},{"key":"12_CR68","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ophtha.2013.10.027","volume":"121","author":"EY Chew","year":"2014","unstructured":"AREDS2-HOME Study Research Group, Chew EY, Clemons TE et al (2014) Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. Ophthalmology 121:535\u2013544. https:\/\/doi.org\/10.1016\/j.ophtha.2013.10.027","journal-title":"Ophthalmology"},{"key":"12_CR69","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1146\/annurev-genom-090413-025610","volume":"15","author":"LG Fritsche","year":"2014","unstructured":"Fritsche LG, Fariss RN, Stambolian D et al (2014) Age-related macular degeneration: genetics and biology coming together. Annu Rev Genomics Hum Genet 15:151\u2013171","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"12_CR70","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/ng.3448","volume":"48","author":"LG Fritsche","year":"2016","unstructured":"Fritsche LG, Igl W, Bailey JNC et al (2016) A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet 48:134\u2013143. https:\/\/doi.org\/10.1038\/ng.3448","journal-title":"Nat Genet"},{"key":"12_CR71","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamaophthalmol.2018.1544","volume":"136","author":"FG Holz","year":"2018","unstructured":"Holz FG, Sadda SR, Busbee B et al (2018) Efficacy and safety of Lampalizumab for geographic atrophy due to age-related macular degeneration: chroma and spectri phase 3 randomized clinical trials. JAMA Ophthalmol 136:666\u2013677. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.1544","journal-title":"JAMA Ophthalmol"},{"key":"12_CR72","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.ophtha.2013.09.044","volume":"121","author":"Z Yehoshua","year":"2014","unstructured":"Yehoshua Z, Alexandre de Amorim Garcia Filho C, Nunes RP et al (2014) Systemic complement inhibition with Eculizumab for geographic atrophy in age-related macular degeneration. Ophthalmology 121:693\u2013701. https:\/\/doi.org\/10.1016\/j.ophtha.2013.09.044","journal-title":"Ophthalmology"},{"key":"12_CR73","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1080\/14712598.2017.1356817","volume":"17","author":"NA Moore","year":"2017","unstructured":"Moore NA, Bracha P, Hussain RM et al (2017) Gene therapy for age-related macular degeneration. Expert Opin Biol Ther 17:1235\u20131244. https:\/\/doi.org\/10.1080\/14712598.2017.1356817","journal-title":"Expert Opin Biol Ther"},{"key":"12_CR74","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.18-24426","volume":"59","author":"MS Singh","year":"2018","unstructured":"Singh MS, MacLaren RE (2018) Stem cell treatment for age-related macular degeneration: the challenges. Investig Opthalmology Vis Sci 59:AMD78. https:\/\/doi.org\/10.1167\/iovs.18-24426","journal-title":"Investig Opthalmology Vis Sci"},{"key":"12_CR75","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1200\/JCO.1988.6.2.380","volume":"6","author":"MJ Manyak","year":"1988","unstructured":"Manyak MJ, Russo A, Smith PD, Glatstein E (1988) Photodynamic therapy. J Clin Oncol 6:380\u2013391. https:\/\/doi.org\/10.1200\/JCO.1988.6.2.380","journal-title":"J Clin Oncol"},{"key":"12_CR76","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/1011-1344(89)80035-1","volume":"3","author":"CN Zhou","year":"1989","unstructured":"Zhou CN (1989) Mechanisms of tumor necrosis induced by photodynamic therapy. J Photochem Photobiol B 3:299\u2013318","journal-title":"J Photochem Photobiol B"},{"key":"12_CR77","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1001\/archopht.1995.01100060136048","volume":"113","author":"JW Miller","year":"1995","unstructured":"Miller JW, Walsh AW, Kramer M et al (1995) Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol (Chicago Ill 1960) 113:810\u2013818","journal-title":"Arch Ophthalmol (Chicago Ill 1960)"},{"key":"12_CR78","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/S0161-6420(13)31079-3","volume":"101","author":"U Schmidt-Erfurth","year":"1994","unstructured":"Schmidt-Erfurth U, Hasan T, Gragoudas E et al (1994) Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 101:1953\u20131961","journal-title":"Ophthalmology"},{"key":"12_CR79","first-page":"198","volume":"119","author":"NM Bressler","year":"2001","unstructured":"Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol (Chicago Ill 1960) 119:198\u2013207","journal-title":"Arch Ophthalmol (Chicago Ill 1960)"},{"key":"12_CR80","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0002-9394(01)00967-9","volume":"131","author":"Verteporfin In Photodynamic Therapy Study Group","year":"2001","unstructured":"Verteporfin In Photodynamic Therapy Study Group (2001) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 131:541\u2013560","journal-title":"Am J Ophthalmol"},{"key":"12_CR81","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","volume":"135","author":"A Koh","year":"2017","unstructured":"Koh A, Lai TYY, Takahashi K et al (2017) Efficacy and safety of Ranibizumab with or without Verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. JAMA Ophthalmol 135:1206. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.4030","journal-title":"JAMA Ophthalmol"},{"key":"12_CR82","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1053\/sonc.2002.37264","volume":"29","author":"N Ferrara","year":"2002","unstructured":"Ferrara N (2002) Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29:10\u201314. https:\/\/doi.org\/10.1053\/sonc.2002.37264","journal-title":"Semin Oncol"},{"key":"12_CR83","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1042\/CS20040370","volume":"109","author":"H Takahashi","year":"2005","unstructured":"Takahashi H, Shibuya M (2005) The vascular endothelial growth factor (VEGF)\/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 109:227\u2013241. https:\/\/doi.org\/10.1042\/CS20040370","journal-title":"Clin Sci (Lond)"},{"key":"12_CR84","doi-asserted-by":"publisher","first-page":"7788","DOI":"10.1074\/jbc.271.13.7788","volume":"271","author":"BA Keyt","year":"1996","unstructured":"Keyt BA, Berleau LT, Nguyen HV et al (1996) The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 271:7788\u20137795","journal-title":"J Biol Chem"},{"key":"12_CR85","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1210\/mend-5-12-1806","volume":"5","author":"KA Houck","year":"1991","unstructured":"Houck KA, Ferrara N, Winer J et al (1991) The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5:1806\u20131814. https:\/\/doi.org\/10.1210\/mend-5-12-1806","journal-title":"Mol Endocrinol"},{"key":"12_CR86","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrd1955","volume":"5","author":"EWM Ng","year":"2006","unstructured":"Ng EWM, Shima DT, Calias P et al (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5:123\u2013132. https:\/\/doi.org\/10.1038\/nrd1955","journal-title":"Nat Rev Drug Discov"},{"key":"12_CR87","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1056\/NEJMoa042760","volume":"351","author":"ES Gragoudas","year":"2004","unstructured":"Gragoudas ES, Adamis AP, Cunningham ET et al (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805\u20132816. https:\/\/doi.org\/10.1056\/NEJMoa042760","journal-title":"N Engl J Med"},{"key":"12_CR88","doi-asserted-by":"publisher","first-page":"1508.e1","DOI":"10.1016\/j.ophtha.2006.02.064","volume":"113","author":"U Chakravarthy","year":"2006","unstructured":"VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, Chakravarthy U, Adamis AP et al (2006) Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 113:1508.e1\u20131508.25. https:\/\/doi.org\/10.1016\/j.ophtha.2006.02.064","journal-title":"Ophthalmology"},{"key":"12_CR89","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.exer.2007.05.008","volume":"85","author":"J Lowe","year":"2007","unstructured":"Lowe J, Araujo J, Yang J et al (2007) Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res 85:425\u2013430. https:\/\/doi.org\/10.1016\/j.exer.2007.05.008","journal-title":"Exp Eye Res"},{"key":"12_CR90","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431. https:\/\/doi.org\/10.1056\/NEJMoa054481","journal-title":"N Engl J Med"},{"key":"12_CR91","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432\u20131444. https:\/\/doi.org\/10.1056\/NEJMoa062655","journal-title":"N Engl J Med"},{"key":"12_CR92","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK et al (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116:57\u201365.e5. https:\/\/doi.org\/10.1016\/j.ophtha.2008.10.018","journal-title":"Ophthalmology"},{"key":"12_CR93","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara N, Hillan KJ, Gerber H-P, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391\u2013400. https:\/\/doi.org\/10.1038\/nrd1381","journal-title":"Nat Rev Drug Discov"},{"key":"12_CR94","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","volume":"112","author":"S Michels","year":"2005","unstructured":"Michels S, Rosenfeld PJ, Puliafito CA et al (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035\u20131047. https:\/\/doi.org\/10.1016\/j.ophtha.2005.02.007","journal-title":"Ophthalmology"},{"key":"12_CR95","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","volume":"36","author":"PJ Rosenfeld","year":"2005","unstructured":"Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:331\u2013335","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"12_CR96","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.ophtha.2010.12.019","volume":"118","author":"FG Holz","year":"2011","unstructured":"Holz FG, Amoaku W, Donate J et al (2011) Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 118:663\u2013671. https:\/\/doi.org\/10.1016\/j.ophtha.2010.12.019","journal-title":"Ophthalmology"},{"key":"12_CR97","doi-asserted-by":"crossref","unstructured":"(2008) Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF trap - Regeneron, VEGF trap (R1R2), VEGF trap-eye. Drugs R D 9:261\u2013269","DOI":"10.2165\/00126839-200809040-00006"},{"key":"12_CR98","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/bjo.2007.134874","volume":"92","author":"MW Stewart","year":"2008","unstructured":"Stewart MW, Rosenfeld PJ (2008) Predicted biological activity of intravitreal VEGF trap. Br J Ophthalmol 92:667\u2013668. https:\/\/doi.org\/10.1136\/bjo.2007.134874","journal-title":"Br J Ophthalmol"},{"key":"12_CR99","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V et al (2012) Intravitreal Aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537\u20132548. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006","journal-title":"Ophthalmology"},{"key":"12_CR100","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","volume":"124","author":"PU Dugel","year":"2017","unstructured":"Dugel PU, Jaffe GJ, Sallstig P et al (2017) Brolucizumab versus Aflibercept in participants with neovascular age-related macular degeneration: A randomized trial. Ophthalmology 124:1296\u20131304. https:\/\/doi.org\/10.1016\/j.ophtha.2017.03.057","journal-title":"Ophthalmology"},{"key":"12_CR101","doi-asserted-by":"publisher","unstructured":"Dugel PU, Koh A, Ogura Y et al (2020) HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of Brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127. https:\/\/doi.org\/10.1016\/J.OPHTHA.2019.04.017","DOI":"10.1016\/J.OPHTHA.2019.04.017"},{"key":"12_CR102","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","volume":"148","author":"GA Lalwani","year":"2009","unstructured":"Lalwani GA, Rosenfeld PJ, Fung AE et al (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol 148:43\u201358.e1. https:\/\/doi.org\/10.1016\/j.ajo.2009.01.024","journal-title":"Am J Ophthalmol"},{"key":"12_CR103","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Martin DF, Maguire MG, Fine SL et al (2012) Ranibizumab and Bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 119:1388\u20131398. https:\/\/doi.org\/10.1016\/j.ophtha.2012.03.053","journal-title":"Ophthalmology"},{"key":"12_CR104","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","volume":"382","author":"U Chakravarthy","year":"2013","unstructured":"Chakravarthy U, Harding SP, Rogers CA et al (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet (London, England) 382:1258\u20131267. https:\/\/doi.org\/10.1016\/S0140-6736(13)61501-9","journal-title":"Lancet (London, England)"},{"key":"12_CR105","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ophtha.2015.09.018","volume":"123","author":"K Berg","year":"2016","unstructured":"Berg K, Hadzalic E, Gjertsen I et al (2016) Ranibizumab or Bevacizumab for Neovascular age-related macular degeneration according to the Lucentis compared to Avastin study treat-and-extend protocol. Ophthalmology 123:51\u201359. https:\/\/doi.org\/10.1016\/j.ophtha.2015.09.018","journal-title":"Ophthalmology"},{"key":"12_CR106","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ophtha.2014.07.041","volume":"122","author":"K Berg","year":"2015","unstructured":"Berg K, Pedersen TR, Sandvik L, Bragad\u00f3ttir R (2015) Comparison of Ranibizumab and Bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 122:146\u2013152. https:\/\/doi.org\/10.1016\/j.ophtha.2014.07.041","journal-title":"Ophthalmology"},{"key":"12_CR107","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","volume":"125","author":"R Silva","year":"2018","unstructured":"Silva R, Berta A, Larsen M et al (2018) Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with Ranibizumab from the TREND study. Ophthalmology 125:57\u201365. https:\/\/doi.org\/10.1016\/j.ophtha.2017.07.014","journal-title":"Ophthalmology"},{"key":"12_CR108","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3928\/23258160-20150610-08","volume":"46","author":"NZ Gregori","year":"2015","unstructured":"Gregori NZ, Flynn HW, Schwartz SG et al (2015) Current infectious endophthalmitis rates after Intravitreal injections of anti-vascular endothelial growth factor agents and outcomes of treatment. Ophthalmic Surg Lasers Imaging Retina 46:643\u2013648. https:\/\/doi.org\/10.3928\/23258160-20150610-08","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"12_CR109","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1097\/IAE.0b013e31820a67e4","volume":"31","author":"CA McCannel","year":"2011","unstructured":"McCannel CA (2011) Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina 31:654\u2013661. https:\/\/doi.org\/10.1097\/IAE.0b013e31820a67e4","journal-title":"Retina"},{"key":"12_CR110","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ajo.2016.02.028","volume":"165","author":"N Rayess","year":"2016","unstructured":"Rayess N, Rahimy E, Storey P et al (2016) Postinjection endophthalmitis rates and characteristics following intravitreal Bevacizumab, Ranibizumab, and Aflibercept. Am J Ophthalmol 165:88\u201393. https:\/\/doi.org\/10.1016\/j.ajo.2016.02.028","journal-title":"Am J Ophthalmol"},{"key":"12_CR111","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.oret.2016.09.005","volume":"1","author":"AT Thavikulwat","year":"2017","unstructured":"Thavikulwat AT, Jacobs-El N, Kim JS et al (2017) Evolution of geographic atrophy in participants treated with Ranibizumab for neovascular age-related macular degeneration. Ophthalmol Retin 1:34\u201341. https:\/\/doi.org\/10.1016\/j.oret.2016.09.005","journal-title":"Ophthalmol Retin"},{"key":"12_CR112","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1136\/bjo.2010.180729","volume":"95","author":"TJ Good","year":"2011","unstructured":"Good TJ, Kimura AE, Mandava N, Kahook MY (2011) Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 95:1111\u20131114. https:\/\/doi.org\/10.1136\/bjo.2010.180729","journal-title":"Br J Ophthalmol"},{"key":"12_CR113","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/IAE.0b013e318261a6f7","volume":"33","author":"QV Hoang","year":"2013","unstructured":"Hoang QV, Tsuang AJ, Gelman R et al (2013) Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy. Retina 33:179\u2013187. https:\/\/doi.org\/10.1097\/IAE.0b013e318261a6f7","journal-title":"Retina"},{"key":"12_CR114","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS et al (2013) Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 120:2292\u20132299. https:\/\/doi.org\/10.1016\/j.ophtha.2013.03.046","journal-title":"Ophthalmology"},{"key":"12_CR115","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1097\/IAE.0b013e3181a2c1c3","volume":"29","author":"F Forooghian","year":"2009","unstructured":"Forooghian F, Cukras C, Meyerle CB et al (2009) Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina 29:723\u2013731. https:\/\/doi.org\/10.1097\/IAE.0b013e3181a2c1c3","journal-title":"Retina"},{"key":"12_CR116","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/bjo.2011.204685","volume":"96","author":"JL Gasperini","year":"2012","unstructured":"Gasperini JL, Fawzi AA, Khondkaryan A et al (2012) Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol 96:14\u201320. https:\/\/doi.org\/10.1136\/bjo.2011.204685","journal-title":"Br J Ophthalmol"},{"key":"12_CR117","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1136\/bjophthalmol-2013-304829","volume":"98","author":"WB Messenger","year":"2014","unstructured":"Messenger WB, Campbell JP, Faridi A et al (2014) Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration. Br J Ophthalmol 98:1205\u20131207. https:\/\/doi.org\/10.1136\/bjophthalmol-2013-304829","journal-title":"Br J Ophthalmol"},{"issue":"Suppl 1","key":"12_CR118","doi-asserted-by":"publisher","first-page":"i17","DOI":"10.1136\/bjophthalmol-2013-304474","volume":"98","author":"PJ Ferrone","year":"2014","unstructured":"Ferrone PJ, Anwar F, Naysan J et al (2014) Early initial clinical experience with intravitreal aflibercept for wet age-related macular degeneration. Br J Ophthalmol 98(Suppl 1):i17\u2013i21. https:\/\/doi.org\/10.1136\/bjophthalmol-2013-304474","journal-title":"Br J Ophthalmol"},{"key":"12_CR119","doi-asserted-by":"publisher","first-page":"553","DOI":"10.5301\/ejo.5000268","volume":"23","author":"M Aslankurt","year":"2013","unstructured":"Aslankurt M, Aslan L, Aksoy A et al (2013) The results of switching between 2 anti-VEGF drugs, bevacizumab and ranibizumab, in the treatment of neovascular age-related macular degeneration. Eur J Ophthalmol 23:553\u2013557. https:\/\/doi.org\/10.5301\/ejo.5000268","journal-title":"Eur J Ophthalmol"},{"key":"12_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2013.04.009","volume":"e1","author":"AP Schachat","year":"2013","unstructured":"Schachat AP (2013) Switching anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration. Am J Ophthalmol 156 e1:1\u20132. https:\/\/doi.org\/10.1016\/j.ajo.2013.04.009","journal-title":"Am J Ophthalmol 156"},{"key":"12_CR121","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/eye.2014.64","volume":"28","author":"C Ehlken","year":"2014","unstructured":"Ehlken C, Jungmann S, B\u00f6hringer D et al (2014) Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD. Eye (Lond) 28:538\u2013545. https:\/\/doi.org\/10.1038\/eye.2014.64","journal-title":"Eye (Lond)"},{"key":"12_CR122","doi-asserted-by":"publisher","first-page":"913","DOI":"10.3928\/23258160-20181203-01","volume":"49","author":"CC Wykoff","year":"2018","unstructured":"Wykoff CC, Hariprasad SM, Zhou B (2018) Innovation in Neovascular age-related macular degeneration: consideration of Brolucizumab, Abicipar, and the port delivery system. Ophthalmic Surgery, Lasers Imaging Retina 49:913\u2013917. https:\/\/doi.org\/10.3928\/23258160-20181203-01","journal-title":"Ophthalmic Surgery, Lasers Imaging Retina"},{"key":"12_CR123","doi-asserted-by":"publisher","unstructured":"Campochiaro PA, Marcus DM, Awh CC et al (2019) The port delivery system with Ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial. Ophthalmology 126. https:\/\/doi.org\/10.1016\/J.OPHTHA.2019.03.036","DOI":"10.1016\/J.OPHTHA.2019.03.036"},{"key":"12_CR124","unstructured":"Siddiqui F, Aziz A, Khanani A (2020) retinal physician - gene therapy for neovascular AMD. https:\/\/www.retinalphysician.com\/issues\/2020\/special-edition-2020\/gene-therapy-for-neovascular-amd. Accessed 17 Mar 2020"},{"key":"12_CR125","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3390\/jcm4020343","volume":"4","author":"Y Yonekawa","year":"2015","unstructured":"Yonekawa Y, Miller JW, Kim IK (2015) Age-related macular degeneration: advances in management and diagnosis. J Clin Med 4:343\u2013359","journal-title":"J Clin Med"}],"container-title":["Advances in Experimental Medicine and Biology","Age-related Macular Degeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-66014-7_12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T15:25:21Z","timestamp":1618327521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-030-66014-7_12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783030660130","9783030660147"],"references-count":125,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-66014-7_12","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"type":"print","value":"0065-2598"},{"type":"electronic","value":"2214-8019"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"14 April 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}